Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - British journal of …, 2018 - nature.com
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy
M Zhou, X Chen, H Zhang, L Xia, X Tong… - Cancer …, 2019 - Wiley Online Library
Abstract Background On May 8, 2018, the China National Medical Products Administration
(NMPA) approved anlotinib, an orally administered anti‐angiogenesis inhibitor, for the …
(NMPA) approved anlotinib, an orally administered anti‐angiogenesis inhibitor, for the …
Anlotinib: first global approval
YY Syed - Drugs, 2018 - Springer
Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …
Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
X Si, L Zhang, H Wang, X Zhang, M Wang… - Thoracic …, 2019 - Wiley Online Library
Background Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial
growth factor receptor, fibroblast growth factor receptor, platelet‐derived growth factor …
growth factor receptor, fibroblast growth factor receptor, platelet‐derived growth factor …
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
X Zhang, L Zeng, Y Li, Q Xu, H Yang, A Lizaso… - Cancer Immunology …, 2021 - Springer
Background This study evaluated the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
G Shen, F Zheng, D Ren, F Du, Q Dong, Z Wang… - Journal of hematology & …, 2018 - Springer
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …
[HTML][HTML] Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC
T Chu, R Zhong, H Zhong, BO Zhang, W Zhang… - Journal of Thoracic …, 2021 - Elsevier
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …
angiogenesis has been well established, evidence supporting the chemo-free combination …
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
J Lu, H Zhong, T Chu, X Zhang, R Li… - European …, 2019 - Eur Respiratory Soc
Background Anlotinib has been demonstrated in clinical trials to be effective in prolonging
the progression-free survival (PFS) and overall survival (OS) of refractory advanced …
the progression-free survival (PFS) and overall survival (OS) of refractory advanced …
[HTML][HTML] Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer
JCH Yang, SHI Ou, L De Petris, S Gadgeel… - Journal of Thoracic …, 2017 - Elsevier
Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …
phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety …